[8-K] P10, Inc. Reports Material Event
P10, Inc. reported that it entered into interest-rate derivative arrangements tied to its Amended and Restated Credit Agreement dated August 1, 2024. The company sold a 3‑month term SOFR floor at 2.310% and purchased a cap at 4.250% on a notional amount of $211,250,000. The filing states these instruments were executed to manage the variable interest-rate risk associated with borrowings under the credit facility. The disclosure is signed by Amanda Coussens, Chief Financial Officer, and dated September 18, 2025.
- Established interest-rate hedges covering a material notional of $211,250,000 to address borrowing rate volatility
- Clear alignment of the derivatives with the company’s Amended and Restated Credit Agreement dated August 1, 2024
- Documented counterparty and agent bank roles including JPMorgan Chase Bank, N.A. as administrative and collateral agent
- None.
Insights
TL;DR: Company established $211.25M SOFR-linked hedges to manage variable borrowing costs under its credit facility.
The filing documents a straightforward hedging trade: sale of a 3-month SOFR floor at 2.310% and purchase of a 4.250% cap on a $211,250,000 notional. This structure indicates the company is taking explicit steps to limit exposure to rising short-term SOFR while exchanging certain rate-floor economics. The instruments are linked to the Amended and Restated Credit Agreement dated August 1, 2024, which aligns the hedge with the company’s borrowing profile. Disclosure is concise and factual, without performance metrics or valuation details.
TL;DR: The derivatives appear designed to manage interest-rate volatility on outstanding credit facility borrowings.
The positions—selling a 2.310% SOFR floor and buying a 4.250% cap—are explicitly described as risk-management actions for variable-rate borrowings under the company’s credit agreement. The filing provides notional size but does not disclose hedge accounting treatment, counterparty details beyond agent banks, or mark-to-market exposures. The lack of valuation and counterparty specifics limits assessment of counterparty concentration and balance-sheet effects.